Combination therapy with intravitreal bevacizumab and macular grid and scatter laser photocoagulation in patients with macular edema secondary to branch retinal vein occlusion

Journal of Ocular Pharmacology and Therapeutics

Volumn 31, Issue 3, 2015, Pages 179-185

  Yang, Chang Sue ^a,b,c   Liu, Jorn Hon ^b,d   Chung, Yu Chien ^a,b   Chou, Yu Bai ^a,b   Hung, Kuo Hsuan ^b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d CHENG HSIN GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CARDIOVASCULAR DISEASE; CASE STUDY; CENTRAL MACULAR THICKNESS; CHRONOTHERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DRUG EFFICACY; ENDOPHTHALMITIS; FEMALE; GLAUCOMA; HUMAN; INTERVENTION STUDY; LASER COAGULATION; LOADING DRUG DOSE; MACULAR EDEMA; MACULAR GRID AND SCATTER LASER PHOTOCOAGULATION; MALE; MIDDLE AGED; OPHTHALMIC LASER; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PROSPECTIVE STUDY; REBOUND; REPEATED DRUG DOSE; RETINA DETACHMENT; RETINA ISCHEMIA; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; THROMBOEMBOLISM; TREATMENT RESPONSE; UVEITIS; VISION; VISUAL ACUITY; VITREOUS HEMORRHAGE; COMPLICATION; DRUG EFFECTS; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; OPTICAL COHERENCE TOMOGRAPHY; PROCEDURES; RETINAL VEIN OCCLUSION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; COMBINED MODALITY THERAPY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; LIGHT COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84928107869     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2014.0069     Document Type: Article

References (28)

1. Klein, R., Moss, S.E., Meuer, S.M., and Klein, B.E. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch. Ophthalmol. 126:513-518, 2008.
2. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular oedema in branch vein occlusion. Am. J. Ophthalmol. 98:271-282, 1984.
3. Noma, H., Funatsu, H., Yamasaki, M., et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am. J. Ophthalmol. 140:256-261, 2005.
4. Noma, H., Minamoto, A., Funatsu, H., et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch. Clin. Exp. Ophthalmol. 244:309-315, 2006.
5. Keck, P.J., Hauser, S.D., Krivi, G., et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 246:1309-1312, 1989.
6. Leung, D.W., Cachianes, G., Kuang, W.J., Goeddel, D.V., and Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1306-1309, 1989.
7. Senger, D.R., Connolly, D.T., Van de Water, L., Feder, J., and Dvorak, H.F. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 50:1774-1778, 1990.
8. Antonetti, D.A., Barber, A.J., Hollinger, L.A., et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occudin and zonula occluden 1 A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J. Biol. Chem. 274:23463-23467, 1999.
9. Avery, R.L., Pieramici, D.J., Rabena, M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 113:363-372, 2006.
10. Stahl, A., Agostini, H., Hansen, L.L., and Feltgen, N. Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch. Clin. Exp. Ophthalmol. 245:1429-1436, 2007.
11. Schaal, K.B., Höh, A.E., Scheuerle, A., Schütt, F., and Dithmar, S. Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe. 104:285-289, 2007.
12. Pai, S.A., Shetty, R., Vijayan, P.B., et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am. J. Ophthalmol. 143:601-606, 2007.
13. Rabena, M.D., Pieramici, D.J., Castellarin, A.A., Nasir, M.A., and Avery, R.L. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 27:419-425, 2007.
14. Kriechbaun, K., Michels, S., Prager, F., et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br. J. Ophthalmol. 92:518-522, 2008.
15. Campochiaro, P.A., Heier, J.S., Feiner, L., et al. BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 117:1102-1112, 2010.
16. Brown, D.M., Campochiaro, P.A., Bhisitkul, R.B., et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 118:1594-1602, 2011.
17. Hung, K.H., Lee, S.M., Lee, S.Y., Lee, F.L., and Yang, C.S. Intravitreal bevacizumab (Avastin) in the treatment of macular edema associated with perfused retinal vein occlusion. J. Ocul. Pharmacol. Ther. 26:85-90, 2010.
18. Scott, I.U., Ip, M.S., VanVeldhuisen, P.C., et al. SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study report 6. Arch. Ophthalmol. 127:1115-1128, 2009.
19. Shulman, S., Ferencz, J.R., Gilady, G., Ton, Y., and Assia, E. Prognostic factors for visual acuityimprovement after intravitreal triamcinolone injection. Eye. 21:1067-1070, 2007.
20. Thompson, J.T. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am. J. Ophthalmol. 141:629-637, 2006.
21. Heier, J.S., Campochiaro, P.A., Yau, L., et al. Ranibizumab for macular edema due to retinal vein occlusion: long-term follow-up in the HORIZON trial. Ophthalmology. 119:802-809, 2012.
22. Campochiaro, P.A., Sophie, R., Pearlman, J., et al. Longterm outcomes in patients with retinal vein occlusion treated with ranibizumab: The RETAIN Study. Ophthalmology. 121:209-219, 2014.
23. Campochiaro, P.A., Hafz, G., Shah, S.M., et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol. Ther. 16:791-799, 2008.
24. Pe'er, J., Folberg, R., Itin, A., et al. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology. 105:412-416, 1998.
25. Rosenfeld, P.J., Fung, A.E., and Puliafito, C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg. Lasers Imaging. 36:336-339, 2005.
26. Donati, S., Barosi, P., Bianchi, M., Al Oum, M., and Azzolini, C. Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion. Eur. J. Ophthalmol. 22:607-614, 2012.
27. Campochiaro, P.A., Bhisitkul, R.B., Shapiro, H., and Rubio, R.G. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology. 120:795-802, 2013.
28. Sophie, R., Hafiz, G., Scott, A.W., et al. Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion. Am. J. Ophthalmol. 156:693-705, 2013.